Nexotrav (Timolol, Travoprost)

• Nexotrav is indicated for conditions affecting intraocular pressure within the glaucoma disease family.
• Open‑angle glaucoma: lowers intraocular pressure to slow disease progression.
• Ocular hypertension: reduces pressure to prevent development of glaucoma.
• Elevated intraocular pressure in patients at risk of glaucoma: helps maintain target pressure and protect optic nerve health.

• Timolol acts as a non‑selective beta‑adrenergic antagonist, decreasing aqueous humor production by the ciliary body. Travoprost is a prostaglandin F2α analog that enhances uveoscleral outflow of aqueous humor. The combined actions result in a net reduction of intraocular pressure, addressing the primary pathogenic factor in open‑angle glaucoma and ocular hypertension.

Nexotrav may cause ocular and systemic adverse reactions.

Common Side Effects

• Eye irritation or burning sensation.
• Redness (hyperemia) of the conjunctiva.
• Blurred vision shortly after instillation.
• Itching or mild allergic conjunctivitis.
• Increased eyelash growth.
• Dry eye sensation.

Serious or Rare Side Effects

• Severe allergic reaction with swelling of the eyelid or face.
• Sudden loss of vision or acute ocular pain.
• Systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm.
• Persistent corneal edema or ulceration.
• Worsening of pre‑existing respiratory conditions.

• Before prescribing Nexotrav, clinicians should evaluate patient-specific risk factors.
• Assess cardiovascular status: timolol may lower heart rate and blood pressure.
• Screen for asthma or COPD: beta‑blockade can precipitate bronchospasm.
• Monitor intraocular pressure response after initiation.
• Avoid use in patients with known hypersensitivity to any component.
• Consider pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at room temperature: keep in original container, protect from light and moisture.

Nexotrav can interact with systemic and ocular medications.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers: additive bradycardia or hypotension.
• Other prostaglandin analog eye drops: increased risk of ocular side effects.
• Sympathomimetic ocular agents (e.g., phenylephrine): may reduce IOP‑lowering efficacy.

Moderate Interactions (Monitor Closely):\n- Anticholinergic eye drops: may affect pupil size and comfort.

• Topical anesthetics: potential for increased corneal toxicity.
• Systemic carbonic anhydrase inhibitors: additive intraocular pressure reduction.